Global drugmakers continue promoting their drugs in Russian market, but in a different way
Having abandoned direct advertising of their drugs in Russia after the outbreak of hostilities in Ukraine, global drugmakers are now continuing active spending on the promotion of their products through medical organizations, allocating funds for research and industry events, reports The Pharma Letter’s local correspondent.
According to some Russian media reports and local analysts, in 2023, this spending may increase by 5%, up to 20.5 billion roubles ($223 million). The dynamics may indicate the desire of global players to maintain their share in the Russian market.
Most of this spendings is in the form of payments to doctors and medical organizations. Companies usually pay doctors to participate in conferences and consultations. Also, serious donations are provided for local associations in the form of grants or reimbursement for events and research costs.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze